Our understanding of AAV is increasing
AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases.1,2
AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart2
Recent updates
EULAR 2021
Scientific session recordings highlighting the challenges of balancing clinical priorities in ANCA-associated vasculitis.
ERA-EDTA 2021
Scientific session recording focusing on the reality of remission and relapse aswell as recent clinical evidence regarding glucocorticoids and impact on patient experience.
Kidney week – American Society of Nephrology 2020 (virtual)
Renal disease during maintenance treatment in ANCA associated vasculitis (AAV) remains a problem and glucocorticoid use is high
PosterCountry differences exist in the treatment of ANCA associated vasculitis (AAV) but high dose and prolonged glucocorticoid use is observed across Europe
PosterGerman Congress of Rheumatology 2020
Maintenance treatment for ANCA-associated vasculitis (AAV) in real world practice in Germany - reality of vasculitis remission, relapse and burden of disease.
PosterRare Revolution Magazine – Special edition
The latest edition of Rare Revolution Magazine is dedicated exclusively to ANCA-associated vasculitis. Rare Revolution is a digital magazine giving a voice to patients affected by RARE conditions and the charities that represent and support them – you can view the May edition here.
Interactive tools
Use our interactive educational tools to discover more about ANCA-associated vasculitis (AAV).
AAV World is a brand-new educational game that sheds light on the clinical priorities in AAV in a fun and interactive way. Take part in AAV World and test your skills through a mix of challenges, brainteasers, riddles and quizzes. Or why not join the Rare Disease Investigation Team and put your expertise to the test in our mysterious challenge.
AAV Mechanism of Disease
See how the interaction between neutrophils and the alternative complement system are at the heart of the vasculitis process in AAV.
Patient videos
View stories from Catherine, Jeremy, John & Susan and Shanali on the patient experience page.
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Bekker P, et al. PLoS One 2016;11(10):e0164646.
Little MA, et al. Ann Rheum Dis 2010;69(6):1036−43.
Rutherford P, et al. Arthritis Rheumatol 2018(Suppl 10[Abstract 2723]).
Rutherford P, et al. Patient experience in anti-neutrophil cytoplasmic antibody-associated vasculitis – evolution with time and impact of current therapy. Draft publication.
Robson JC, et al. Rheumatol Int 2018;38(4):675–82.
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Jennette JC, et al. Arthritis Rheum 2013;65(1):1–11.
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
ERA-EDTA 2019 | EULAR 2019
NEW materials to download
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis. Poster >
High burden of disease for AAV patients in Germany - a claims study. Poster >
Economic burden of ANCA-associated vasculitis in Germany - a claims data study. Poster >
Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases. Poster >
Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data. Poster >
Renal damage in ANCA-associated vasculitis in incident and relapsing patients Slide deck >
ALSO NEW from UK Renal Week
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients. Poster >
Electronic consent form
You should only contact us if you are a HCP based outside of the US.
Mind the gap – balancing remission and risk of relapse in AAV
Striking the right balance in AAV
The future of remission maintenance in AAV: new mechanisms, new approaches
Striking the right balance in AAV
State lasciando il sito UnderstandAAV. Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al Decreto Legislavito 219/2006 che regola la pubblicitá dei medicinali per uso umano e le opinion espresso non riflettono necessariamente le posizioni dell’Azienda, né sono da essa avallate
Congress calendar
ERA-EDTA
19-22 May
EULAR
1-4 June
ASN
4-7 November 2021
ACR
5-9 November 2021
20th International Vasculitis and ANCA workshop
3-6 April 2022
Additional Resources
EULAR 2021
Scientific session recordings highlighting the challenges of balancing clinical priorities in ANCA-associated vasculitis.
ERA-EDTA 2021
Scientific session recording focusing on the reality of remission and relapse aswell as recent clinical evidence regarding glucocorticoids and impact on patient experience.
Kidney week – American Society of Nephrology 2020 (virtual)
Renal disease during maintenance treatment in ANCA associated vasculitis (AAV) remains a problem and glucocorticoid use is high
PosterCountry differences exist in the treatment of ANCA associated vasculitis (AAV) but high dose and prolonged glucocorticoid use is observed across Europe
PosterGerman Congress of Rheumatology 2020
Maintenance treatment for ANCA-associated vasculitis (AAV) in real world practice in Germany - reality of vasculitis remission, relapse and burden of disease.
PosterERA-EDTA 2020
Significant burden of disease during maintenance treatment of ANCA-associated vasculitis (AAV) patients in real world practice in Europe.
PosterEULAR 2020
Maintenance treatment for ANCA-associated vasculitis in real world practise in Europe – reality of vasculitis remission and relapse and significant burden of disease.
PresentationPatterns of drug treatment for maintenance phase of ANCA-associated vasculitis (AAV) in real world practise in Europe – prolonged glucocorticoid use is common and various treatment regimes are used.
PosterAntineutrophil Cytoplasmic Antibody-Associated Vasculitis: Achieving and Sustaining Remission while Reducing Organ Damage
Interviews with Three Key Opinion Leaders
European Medical Journal articleVasculitis UK newsletter
ERA-EDTA 2019
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis.
PosterHigh burden of disease for AAV patients in Germany - a claims study.
PosterRenal damage in ANCA-associated vasculitis in incident and relapsing patients.
Slide deckVasculitis 2019 Workshop
Comorbidity, adverse events and infections are major concerns in real world management of ANCA-associated vasculitis.
Abstract PosterUK Renal week 2019
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients.
PosterAdverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases.
PosterSeverity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data.
PosterBSR 2018
Management of ANCA-associated vasculitis in the UK: a complex pathway of patient referral, diagnosis, and treatment.
PosterASN 2018
Patient Experience in ANCA-Associated Vasculitis - Challenges from Diagnosis and Need for New Approaches.
Abstract PosterPatients with Relapsing ANCA-Associated Vasculitis (AAV) Experience Unmet Needs around Remission Induction and Therapy Related Adverse Events.
Abstract PosterReal World Experience in ANCA-Associated Vasculitis (AAV) – A Complex Pathway of Patient Referral, Diagnosis, and Management.
Abstract PosterPatient Support Organisations
Vasculitis International
Europe
www.vasculitis.eu
Selbsthilfe Vaskulitis e.V.
Germany
www.vaskulitisverein-rlp.de
Associazione Pazienti della Sindrome di Churg Strauss
Italy
www.apacs-egpa.org
Suomen Vaskuliittiyhdistys ry
Finland
www.vaskuliittiyhdistys.fi
Selbsthilfe Vaskulitis Mainz
Germany
vaskulitis-mainz@gmx.de
Vasculitis Stichting
Netherlands
www.vasculitis.nl
Association Vascularites
France/Belgium
www.association-vascularites.org
Vasculitis Ireland
Ireland
www.vasculitis-ia.org
Vasculitis UK
United Kingdom
www.vasculitis.org.uk
